Edition:
India

Luye Pharma Group Ltd (2186.HK)

2186.HK on Hong Kong Stock

6.22HKD
17 Jul 2019
Change (% chg)

HK$0.33 (+5.60%)
Prev Close
HK$5.89
Open
HK$5.86
Day's High
HK$6.30
Day's Low
HK$5.86
Volume
38,331,111
Avg. Vol
13,495,270
52-wk High
HK$8.80
52-wk Low
HK$4.88

Latest Key Developments (Source: Significant Developments)

Luye Pharma Group Announces Proposed Issue Of US$300 mln 1.50 Pct. Convertible Bonds Due 2024
Tuesday, 25 Jun 2019 

June 25 (Reuters) - Luye Pharma Group Ltd <2186.HK>::PROPOSED ISSUE OF US$300 MILLION 1.50 PER CENT. CONVERTIBLE BONDS DUE 2024.  Full Article

Pharma Mar And Luye Pharma Sign Deal For Development And Sale Of Lurbinectedin In China Territories
Friday, 26 Apr 2019 

April 26 (Reuters) - Pharma Mar SA ::PHARMAMAR AND LUYE PHARMA <<<2186.HK>>> SIGN LICENSE AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF LURBINECTEDIN IN CHINA TERRITORIES.TO RECEIVE UP-FRONT PAYMENT OF $5 MILLION .OTHER PAYMENTS WILL FOLLOW FOR REGULATORY MILESTONES AND, IN ADDITION, FOR SALES AND ROYALTIES.LUYE PHARMA TO DEVELOP LURBINECTEDIN IN SCLC IN CHINA, WHILE PHARMAMAR TO RETAIN EXCLUSIVE PRODUCTION RIGHTS FOR THE COMPOUND.  Full Article

Luye Pharma Group Posts FY Profit Attributable Rmb1,303.4 Mln
Thursday, 28 Mar 2019 

March 28 (Reuters) - Luye Pharma Group Ltd <2186.HK>::FY REVENUE RMB5,173.4 MILLION, UP 35.6 PERCENT.FY PROFIT ATTRIBUTABLE RMB1,303.4 MILLION, UP 32.8 PERCENT.BOARD PROPOSES A FINAL DIVIDEND OF RMB0.057 PER SHARE.  Full Article

Luye Pharma says Innovative Drug Risperidone Extended Release Microspheres For Injection Reaches Final Stage Of NDA Process
Monday, 31 Dec 2018 

Dec 30 (Reuters) - Luye Pharma Group Ltd <2186.HK>::LUYE PHARMA GROUP ANNOUNCES INNOVATIVE DRUG RISPERIDONE EXTENDED RELEASE MICROSPHERES FOR INJECTION HAS REACHED FINAL STAGE OF NDA PROCESS.SUCCESSFULLY REACHED AN AGREEMENT WITH FDA TO WAIVE ALL PAEDIATRIC CLINICAL STUDIES OF LY03004.OBTAINED FDA'S APPROVAL OF USING RYKINDO AS LY03004'S BRAND NAME FOR TREATMENT OF SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER.  Full Article

Luye Pharma Group Says Unit To Acquire 2 Biological Antibody Drugs Under R&D For RMB500 Mln
Friday, 21 Dec 2018 

Dec 21 (Reuters) - Luye Pharma Group Ltd <2186.HK>::UNIT TO ACQUIRE 2 BIOLOGICAL ANTIBODY DRUGS UNDER RESEARCH AND DEVELOPMENT FOR RMB500 MILLION FROM SHANDONG BOAN BIOLOGICAL TECHNOLOGY.  Full Article

Luye Pharma Group Says LY03003 Drug Approved To Proceed To Phase III Clinical Trials In China
Tuesday, 10 Apr 2018 

April 10 (Reuters) - Luye Pharma Group Ltd <2186.HK>::LY03003 OBTAINED APPROVAL FROM CHINA FOOD AND DRUG ADMINISTRATION TO PROCEED TO PHASE III CLINICAL TRIALS IN CHINA.  Full Article

Luye Pharma Group Announces collaboration With Excel Biopharma
Wednesday, 21 Mar 2018 

March 21 (Reuters) - Luye Pharma Group <2186.HK>::Immuno-Oncology Antibody Drug Development Collaboration With Excel Biopharm.‍GROUP ENTERED INTO A COLLABORATION AND LICENSE AGREEMENT WITH EXCEL BIOPHARMA LLC​.  Full Article

Luye Pharma Group Says ‍Rotigotine Exempted From Phase 2 Dosage Exploration Clinical Trials​
Monday, 12 Mar 2018 

March 12 (Reuters) - Luye Pharma Group Ltd <2186.HK>::‍ROTIGOTINE EXTENDED RELEASE MICROSPHERES FOR INJECTION IS EXEMPTED FROM PHASE II DOSAGE EXPLORATION CLINICAL TRIALS​.  Full Article

Luye Pharma Group Says ‍CFDA Accepted Clinical Trial Application For Co's Anti-Tumor Drug
Monday, 26 Feb 2018 

Feb 26 (Reuters) - Luye Pharma Group Ltd <2186.HK>::‍CFDA OFFICIALLY ACCEPTED CLINICAL TRIAL APPLICATION FOR ANTI-TUMOR DRUG.  Full Article

Luye Pharma Group Says FDA To Waive Pediatric Clinical Trials Of Schizophrenia Drug
Wednesday, 21 Feb 2018 

Feb 21 (Reuters) - Luye Pharma Group Ltd <2186.HK>::FDA AGREES TO WAIVE PEDIATRIC CLINICAL TRIALS OF SCHIZOPHRENIA DRUG LY03004.FDA'S DECISION WILL SIGNIFICANTLY REDUCE RESEARCH AND DEVELOPMENT COST.  Full Article